Motixafortide
- Generic Name
- Motixafortide
- Brand Names
- Aphexda
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 664334-36-5
- Unique Ingredient Identifier
- DA9G065962
- Background
Motixafortide is a cyclic peptide hematopoietic stem cell mobilizer used to improve stem cell collection prior to autologous transplantation. Hematopoietic stem cell transplantation (HSCT) is commonly employed in the context of hematologic cancers - high-dose chemotherapy regimens destroy cancerous blood cells, which are then replaced via infusion of the pat...
- Indication
Motixafortide is indicated for use in combination with filgrastim to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma.
- Associated Conditions
- -
- Associated Therapies
- Mobilization of hematopoietic stem cells
A Pharmacodynamic Study of the Apheresis Product of Multiple Myeloma Patients Undergoing Quad-induction Followed by Motixafortide + G-CSF Mobilization
- First Posted Date
- 2024-08-09
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 20
- Registration Number
- NCT06547112
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
SCD Stem Cell Mobilization and Apheresis Using Motixafortide
- First Posted Date
- 2024-06-04
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 15
- Registration Number
- NCT06442761
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Motixafortide and Natalizumab to Mobilize CD34+ Hematopoietic Stem Cells for Gene Therapies in Sickle Cell Disease (SCD)
- Conditions
- Interventions
- First Posted Date
- 2022-11-16
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 10
- Registration Number
- NCT05618301
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2020-09-09
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Gulam Manji
- Target Recruit Count
- 10
- Registration Number
- NCT04543071
- Locations
- 🇺🇸
Columbia University Irving Medical Center, New York, New York, United States
🇺🇸Brown University, Providence, Rhode Island, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.